Ezz El Din, M., Salah, R., Kamel, T., Nagy, A. (2022). Evaluation of the Effect of Combination Chemotherapy with Five-day Infusion of Fluorouracil plus Vinorelbine in Pretreated Metastatic Breast Cancer Patients. test, 88(1), 2554-2560. doi: 10.21608/ejhm.2022.239189
Mai Ezz El Din; Rasha Salah; Tarek Kamel; Ahmed Nagy. "Evaluation of the Effect of Combination Chemotherapy with Five-day Infusion of Fluorouracil plus Vinorelbine in Pretreated Metastatic Breast Cancer Patients". test, 88, 1, 2022, 2554-2560. doi: 10.21608/ejhm.2022.239189
Ezz El Din, M., Salah, R., Kamel, T., Nagy, A. (2022). 'Evaluation of the Effect of Combination Chemotherapy with Five-day Infusion of Fluorouracil plus Vinorelbine in Pretreated Metastatic Breast Cancer Patients', test, 88(1), pp. 2554-2560. doi: 10.21608/ejhm.2022.239189
Ezz El Din, M., Salah, R., Kamel, T., Nagy, A. Evaluation of the Effect of Combination Chemotherapy with Five-day Infusion of Fluorouracil plus Vinorelbine in Pretreated Metastatic Breast Cancer Patients. test, 2022; 88(1): 2554-2560. doi: 10.21608/ejhm.2022.239189

Evaluation of the Effect of Combination Chemotherapy with Five-day Infusion of Fluorouracil plus Vinorelbine in Pretreated Metastatic Breast Cancer Patients

The Egyptian Journal of Hospital Medicine
Article 43, Volume 88, Issue 1, July 2022, Pages 2554-2560    PDF (557.08 K)
Document Type: Original Article
DOI: 10.21608/ejhm.2022.239189
Authors
Mai Ezz El Din* ; Rasha Salah; Tarek Kamel; Ahmed Nagy
Abstract
Background: Continuous infusion (CI) of 5-fluorouracil (5FU) and vinorelbine, individually and in combination, has been proven in several studies to be active and well tolerated for advanced pretreated breast cancer.
Objective: This study sought to evaluate the clinical activity and side effects of their combination in pretreated metastatic breast cancer patients.
Patients and Methods: This retrospective study collected and analysed the medical records of fifty-four patients who attended El-Salam Oncology Center and Ain Shams University Hospitals, Department of Clinical Oncology during the period from July 2013 to June 2018. Combination chemotherapy received was 5FU 600 mg/m2/d for 5 consecutive days as a CI and vinorelbine 25 mg/m2 on days 1 and 5 as a short intravenous (IV) infusion every 3 weeks.
Results: Eleven (20.4%) complete responses, 20 (37%) partial responses and 14 (25.9%) stable disease were documented, accounting for a clinical benefit rate of 83.3%. The median progression free survival was 6.8 months. The median overall survival (mOS) was 25.8 months. Treatment was well tolerated, with grade 3 anemia, febrile neutropenia and stomatitis in 9.3%, 5.6% and 1.9% respectively as the main adverse reactions.
Conclusions: This drug combination is active in metastatic previously treated breast cancer patients with an acceptable toxicity profile and continues to be present in the treatment armamentarium in this setting.
 
Keywords
Chemotherapy; Fluorouracil (Infusion); Metastatic Breast Cancer; Vinorelbine
Statistics
Article View: 216
PDF Download: 414